Our data is in agreement with an impairment of p53 expression in bladder cancer, viewed by increased immunostaining in the BBN-treated rats, both in pre-neoplastic (hypertrophic) and neoplastic (papillary tumors) regions. This evidence concerns the gene TP53 and urinary bladder cancer.